Evotec AG (NASDAQ:EVTCY) | Finanzwire

Basculer en Français

11005	Companies
241109	Keywords
169692	Articles
129793	Press releases

Home
Companies
Evotec AG

BRIEF

published on 09/09/2026 at 07:35, 7 days 14 hours ago

Evotec Advances Antibodies Against Orthopoxvirus to Clinical Trials

Phase 1 Clinical Trial Evotec SE Orthopoxvirus Monoclonal Antibodies Biodefense Preparedness
PRESS RELEASE

published on 09/09/2026 at 07:30, 7 days 14 hours ago

Just – Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
Just \/ Evotec Biologics advances investigational antibodies against orthopoxviruses into Phase 1 clinical studies under U.S. Department of War Accelerated Antibodies Program, supporting biodefense preparedness

Biodefense U.S. Department Of War Orthopoxviruses Just \/ Evotec Biologics Phase 1 Clinical Studies
BRIEF

published on 09/02/2026 at 07:35, 14 days 14 hours ago

Evotec and Plectonic Collaborate on T-Cell Approaches for Solid Tumors

Evotec SE Solid Tumors Immunotherapy Plectonic Biotech T-cell Engagement
PRESS RELEASE

published on 09/02/2026 at 07:30, 14 days 14 hours ago

Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Evotec SE and Plectonic Biotech collaborate on a new T-cell-engaging immunotherapy approach for solid tumors, combining BiTco costimulatory platform with LOGIBODY technology

Evotec SE Solid Tumors Immunotherapy Plectonic Biotech T-cell-engaging
BRIEF

published on 08/06/2026 at 07:35, 1 month 10 days ago

Evotec and Odyssey Therapeutics Join Forces in AI-Driven Drug Discovery

Evotec SE Inflammatory Diseases Autoimmune Diseases Odyssey Therapeutics AI-driven Discovery
BRIEF

published on 08/06/2026 at 07:35, 1 month 10 days ago

Evotec and Odyssey Therapeutics Form AI-Driven R&D Partnership

Drug Discovery Autoimmune Diseases Milestone Payments Evotec Collaboration AI-driven R&D
PRESS RELEASE

published on 08/06/2026 at 07:30, 1 month 10 days ago

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Evotec SE and Odyssey Therapeutics collaborate on AI-enabled R&D for autoimmune and inflammatory diseases, aiming to discover new treatments. Collaboration combines expertise and technology to accelerate drug discovery

Inflammatory Diseases Autoimmune Diseases Evotec R&D Collaboration Odyssey Therapeutics
PRESS RELEASE

published on 08/06/2026 at 07:30, 1 month 10 days ago

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Evotec SE and Odyssey Therapeutics collaborate on AI-enabled R&D for autoimmune and inflammatory diseases, leveraging expertise and advanced technologies

Evotec SE Inflammatory Diseases Autoimmune Diseases Odyssey Therapeutics AI-enabled R&D
BRIEF

published on 07/13/2026 at 21:25, 2 months 3 days ago

Evotec Adjusts 2026 Financial Outlook Amid Strategic Partnership Delays

Strategic Partnerships Revenue Forecast Cost Savings Evotec Financial Results 2026
BRIEF

published on 07/13/2026 at 21:22, 2 months 3 days ago

Evotec Releases Preliminary Financial Results for 2026

Preliminary Results Financial Outlook Group EBITDA 2026 Forecasts Evotec Revenue

Accesswire

Published on 09/16/2026 at 21:30, 8 minutes ago

Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 4 hours 43 minutes ago

CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 6 hours 38 minutes ago

2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 7 hours 38 minutes ago

Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/16/2026 at 13:30, 8 hours 8 minutes ago

Sterling Extends Core MEPS Copper Zone to 700m; Intersects 200m of 0.53% CuEq Including 102m of 0.81% CuEq

View all ACCESSWIRE

EQS Group

Published on 09/16/2026 at 21:15, 22 minutes ago

Gastech 2026 in Bangkok Converts Global Energy Ambition into Billions of Dollars in Deals
Published on 09/16/2026 at 20:27, 1 hour 10 minutes ago

EQS-Adhoc: REPLOID Group AG resolves to issue convertible notes in an aggregate principal amount of up to EUR 30 million
Published on 09/16/2026 at 19:05, 2 hours 32 minutes ago

EcoFlow to showcase its open home energy ecosystem at Solar & Storage Live Zurich 2026
Published on 09/16/2026 at 18:22, 3 hours 15 minutes ago

EQS-Adhoc: elumeo SE resolves on a capital increase against cash contributions, ex-cluding pre-emptive rights, and a move to the Scale segment
Published on 09/16/2026 at 18:11, 3 hours 26 minutes ago

EQS-Adhoc: Berentzen-Gruppe Aktiengesellschaft confirms rumours regarding negotiations on a voluntary takeover offer by SAZERAC COMPANY, INC.

Les Echos

Published on 09/16/2026 at 20:46, 51 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 3 hours 53 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 3 hours 53 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 14 hours 38 minutes ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 3 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE